February 12, 2018

Biostage names regenerative medicine expert to board

Courtesy/Biostage

Charles Cox.

Holliston biotech Biostage has appointed another medical professional to its scientific advisory board as the company continues its makeover following a near bankruptcy position just months ago.

Charles Cox, director of the children's regenerative medicine program at University of Texas Health McGovern Medical School, was appointed to the board.

Since a $4.2-million investment largely from a group of Chinese investors in the fall, the company has begun a shift to focus on developing bioengineered organ implants to treat conditions of the throat in children.

Cox's experience in pediatric, surgical, cell therapy and cell-based tissue engineering make him particularly well-suited to help guide the company's scientific ventures, said board Co-Chairman Stephen Badylak.

The company already has a relationship with Cox's program. In August, the company announced the use of an esophageal implant in a patient at the University of Texas Health Science Center.

Cox joins Badylak, Joseph Vacanti, and Christine Finck, the last of whom is executive vice president and surgeon-in-chief at Connecticut Children's Medical Center.

Finck was appointed to the board last month, after her hospital invested $100,000 into the company.

"Our technology's ability to attract this prestigious group of experts to our Scientific Advisory Board is a testament to our technology's potential," said Biostage CEO Jim McGorry.

Biostage awarded up to $1.7M grant for preclinical study

Biostage lands $1M investment

Biostage names Chinese investor as board chairman

Biostage appoints children's hospital surgeon to science board

Biostage's science perseveres through dire financial straits

Biostage closes $4.2M investment with Chinese group, Conn. hospital

Biostage combines stock 20:1 to satisfy $4M private investor

Biostage scores $4M private investment, eyes turnaround

Biostage delisting effective Dec. 18

Biostage misses 3Q filing deadline due to financial woes

Biostage lays off 71% of workforce after delisting

Holliston biotech delisted from NASDAQ